Epstein-Barr virus-related post-transplant lymphoproliferative disorders are recognized as a
significant cause of morbidity and mortality in patients undergoing hematopoietic stem cell …

This manuscript represents a review of lymphoblastic leukemia/lymphoma (acute
lymphoblastic leukemia/lymphoblastic lymphoma), acute leukemias of ambiguous lineage …

Purpose Allogeneic hematopoietic cell transplantation (HCT) is curative but is associated
with life-threatening complications. Most deaths occur within the first 2 years after …

We previously demonstrated that autologous natural killer (NK)–cell therapy after
hematopoietic cell transplantation (HCT) is safe but does not provide an antitumor effect. We …

This is the third volume in the new World Health Organization series on histological and
genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered …

Mature donor T cells cause graft-versus-host disease (GVHD), but they are also the main
mediators of the beneficial graft-versus-tumor (GVT) activity of allogeneic bone marrow …

We evaluated HLA-compatible donor leukocyte infusions (DLIs) and HLA-compatible or HLA-
disparate EBV-specific T cells (EBV-CTLs) in 49 hematopoietic cell transplantation …

Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT)
remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases …

Second and higher-order malignancies now comprise about 18% of all incident cancers in
the USA, superseding first primary cancers of the breast, lung, and prostate. The occurrence …

We evaluated 26 901 patients who underwent allogeneic hematopoietic cell transplantation
(HCT) at 271 centers worldwide to define patterns of posttransplantation lymphoproliferative …